Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct;56(10):2610-2612.
doi: 10.1038/s41409-021-01407-6. Epub 2021 Jul 15.

Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation

Madlen Jentzsch  1 , Juliane Grimm  1 , Marius Bill  1 , Johannes Küpper  1 , Donata Backhaus  1 , Dominic Brauer  1 , Julia Schulz  1 , Georg-Nikolaus Franke  1 , Vladan Vucinic  1 , Dietger Niederwieser  1 , Uwe Platzbecker  1 , Sebastian Schwind  2
Affiliations

Measurable residual disease of canonical versus non-canonical DNMT3A, TET2, or ASXL1 mutations in AML at stem cell transplantation

Madlen Jentzsch et al. Bone Marrow Transplant. 2021 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Analysis of DTA mutations at diagnosis and as MRD markers prior to allogeneic HSCT.
A Co-mutational pattern and (B) Distribution of the three ELN2017 risk groups within DNMT3A, TET2, and ASXL1 mutated AML patients at diagnosis. C Overview of VAF levels of persisting DNMT3A, TET2, and ASXL1 mutations and comparison of persisting non-canonical vs canonical DNMT3A or ASXL1 mutations at HSCT. D Cumulative Incidence of Relapse and Overall Survival according to persisting vs non-persisting DTA mutations at HSCT (n = 50). E Cumulative Incidence of Relapse and Overall Survival according to the presence of a non-canonical vs a canonical mutation in patients with persisting DNMT3 or ASXL1 mutations.
See this image and copyright information in PMC

References

    1. Corces-Zimmerman MR, Hong WJ, Weissman IL, Medeiros BC, Majeti R. Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission. Proc Natl Acad Sci USA. 2014;111:2548–53. doi: 10.1073/pnas.1324297111. - DOI - PMC - PubMed
    1. Wong TN, Miller CA, Klco JM, Petti A, Demeter R, Helton NM, et al. Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood. 2016;127:893–7. doi: 10.1182/blood-2015-10-677021. - DOI - PMC - PubMed
    1. Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, et al. Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia. J Clin Oncol. 2018;36:1788–97. doi: 10.1200/JCO.2017.77.6757. - DOI - PMC - PubMed
    1. Gaidzik VI, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, et al. DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia. Leukemia. 2018;32:30–37. doi: 10.1038/leu.2017.200. - DOI - PubMed
    1. Pløen GG, Nederby L, Guldberg P, Hansen M, Ebbesen LH, Jensen UB, et al. Persistence of DNMT3A mutations at long-term remission in adult patients with AML. Br J Haematol. 2014;167:478–86. doi: 10.1111/bjh.13062. - DOI - PubMed

Publication types